Literature DB >> 22563296

α-synuclein, LRRK2 and their interplay in Parkinson's disease.

Guoxiang Liu1, Leonardo Aliaga, Huaibin Cai.   

Abstract

Of the various genetic factors contributing to the pathogenesis of Parkinson's disease (PD), only mutations in α-synuclein (α-syn) and LRRK2 genes cause clinical and neuropathological phenotypes closely resembling the sporadic cases. Therefore, studying the pathophysiological functions of these two PD-related genes is particularly informative in understanding the underlying molecular pathogenic mechanism of the disease. PD-related missense and multiplication mutations in α-syn may cause both early- and late-onset PD, whereas various PD-related LRRK2 missense mutations may contribute to the more common late-onset PD. While intensive studies have been carried out to elucidate the pathogenic properties of PD-related mutant α-syn and LRRK2, our knowledge of their normal functions and their potential genetic interplay remains rudimental. In this review, we summarize the progress made regarding the pathophysiological functions of α-syn, LRRK2 and their interaction in PD, based on the available literature and our unpublished observations.

Entities:  

Year:  2012        PMID: 22563296      PMCID: PMC3343692          DOI: 10.2217/fnl.12.2

Source DB:  PubMed          Journal:  Future Neurol        ISSN: 1479-6708


  91 in total

1.  James Parkinson, born April 11, 1755.

Authors:  A D MORRIS
Journal:  Lancet       Date:  1955-04-09       Impact factor: 79.321

2.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.

Authors:  Ana Maria Cuervo; Leonidas Stefanis; Ross Fredenburg; Peter T Lansbury; David Sulzer
Journal:  Science       Date:  2004-08-27       Impact factor: 47.728

3.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.

Authors:  K A Conway; S J Lee; J C Rochet; T T Ding; R E Williamson; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

4.  Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons.

Authors:  D D Murphy; S M Rueter; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

5.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

6.  Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2.

Authors:  Heather Mortiboys; Krisztina K Johansen; Jan O Aasly; Oliver Bandmann
Journal:  Neurology       Date:  2010-11-30       Impact factor: 9.910

7.  alpha-Synuclein is phosphorylated in synucleinopathy lesions.

Authors:  Hideo Fujiwara; Masato Hasegawa; Naoshi Dohmae; Akiko Kawashima; Eliezer Masliah; Matthew S Goldberg; Jie Shen; Koji Takio; Takeshi Iwatsubo
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

8.  Localization of LRRK2 to membranous and vesicular structures in mammalian brain.

Authors:  Saskia Biskup; Darren J Moore; Fulvio Celsi; Shinji Higashi; Andrew B West; Shaida A Andrabi; Kaisa Kurkinen; Seong-Woon Yu; Joseph M Savitt; Henry J Waldvogel; Richard L M Faull; Piers C Emson; Reidun Torp; Ole P Ottersen; Ted M Dawson; Valina L Dawson
Journal:  Ann Neurol       Date:  2006-11       Impact factor: 10.422

Review 9.  Formation and development of Lewy pathology: a critical update.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

10.  Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.

Authors:  Xianting Li; Qing Jun Wang; Nina Pan; Sangkyu Lee; Yingming Zhao; Brian T Chait; Zhenyu Yue
Journal:  PLoS One       Date:  2011-03-01       Impact factor: 3.240

View more
  15 in total

1.  Inhibitors of LRRK2 as Treatment for Parkinson's Disease: Patent Highlight.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2012-07-27       Impact factor: 4.345

2.  Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways.

Authors:  Vikram Khurana; Jian Peng; Chee Yeun Chung; Pavan K Auluck; Saranna Fanning; Daniel F Tardiff; Theresa Bartels; Martina Koeva; Stephen W Eichhorn; Hadar Benyamini; Yali Lou; Andy Nutter-Upham; Valeriya Baru; Yelena Freyzon; Nurcan Tuncbag; Michael Costanzo; Bryan-Joseph San Luis; David C Schöndorf; M Inmaculada Barrasa; Sepehr Ehsani; Neville Sanjana; Quan Zhong; Thomas Gasser; David P Bartel; Marc Vidal; Michela Deleidi; Charles Boone; Ernest Fraenkel; Bonnie Berger; Susan Lindquist
Journal:  Cell Syst       Date:  2017-01-25       Impact factor: 10.304

3.  A Pooling Genome-Wide Association Study Combining a Pathway Analysis for Typical Sporadic Parkinson's Disease in the Han Population of Chinese Mainland.

Authors:  Yakun Hu; Libing Deng; Jie Zhang; Xin Fang; Puming Mei; Xuebing Cao; Jiari Lin; Yi Wei; Xiong Zhang; Renshi Xu
Journal:  Mol Neurobiol       Date:  2015-07-31       Impact factor: 5.590

4.  The Potential Mutation of GAK Gene in the Typical Sporadic Parkinson's Disease from the Han Population of Chinese Mainland.

Authors:  Jie Zhang; Hanyi Zeng; Lei Zhu; Libing Deng; Xin Fang; Xia Deng; Huiting Liang; Chunyan Tang; Xuebing Cao; Yi Lu; Jiao Li; Xiao Ren; Wenjie Zuo; Xiong Zhang; Renshi Xu
Journal:  Mol Neurobiol       Date:  2015-12-17       Impact factor: 5.590

Review 5.  Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies.

Authors:  Akio Sekigawa; Yoshiki Takamatsu; Kazunari Sekiyama; Makoto Hashimoto
Journal:  Biomolecules       Date:  2015-05-19

6.  Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.

Authors:  Rakel López de Maturana; Valérie Lang; Amaia Zubiarrain; Amaya Sousa; Nerea Vázquez; Ana Gorostidi; Julio Águila; Adolfo López de Munain; Manuel Rodríguez; Rosario Sánchez-Pernaute
Journal:  J Neuroinflammation       Date:  2016-11-18       Impact factor: 8.322

Review 7.  Alpha-synuclein structure, functions, and interactions.

Authors:  Fatemeh Nouri Emamzadeh
Journal:  J Res Med Sci       Date:  2016-05-09       Impact factor: 1.852

8.  LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model.

Authors:  Hien Tran Zhao; Neena John; Vedad Delic; Karli Ikeda-Lee; Aneeza Kim; Andreas Weihofen; Eric E Swayze; Holly B Kordasiewicz; Andrew B West; Laura A Volpicelli-Daley
Journal:  Mol Ther Nucleic Acids       Date:  2017-08-10       Impact factor: 8.886

9.  LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models.

Authors:  Patrícia Silva Guerreiro; Yue Huang; Amanda Gysbers; Danni Cheng; Wei Ping Gai; Tiago Fleming Outeiro; Glenda Margaret Halliday
Journal:  J Mol Med (Berl)       Date:  2012-11-27       Impact factor: 4.599

Review 10.  LRRK2 as a Potential Genetic Modifier of Synucleinopathies: Interlacing the Two Major Genetic Factors of Parkinson's Disease.

Authors:  Cheol Hwan Hyun; Chae Young Yoon; He-Jin Lee; Seung-Jae Lee
Journal:  Exp Neurobiol       Date:  2013-12-31       Impact factor: 3.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.